The effect of Paboliju monoantigen or combined beva bead monoantigen treatment of recurrence GBM was not good

Glioblastoma (GBM) has a very rich blood supply and a high proliferation of tumor blood vessels, which is closely related to the high expression of endoblast growth factor (VEGF).
VEGF inhibitor bevacizumab can prolong the progression-free survival of relapsed glioblastoma, and beva bead monoantigen can also inhibit tumor growth through a variety of mechanisms.
and clinical studies have shown that inhibiting VEGF can enhance the effectiveness of anti-tumor immunotherapy.
Lakshmi Nayak of the Dana-Farber Oncology Institute in Boston, USA, and others conducted randomized clinical phase II. phase II trials in patients with Pembrolizumab single-drug or combined beva-bead monotherapy relapsed GBM.
results were published online november 2020 in Clinical Cancer Research.
Study Methodology The authors included 80 patients with relapsed GBM who had first used beva bead monoantigen, and were randomly assigned to the Paboli pearl monoantigen treatment group (Group A, 50 cases), or the Paboli pearl monoantigen treatment group (Group B, 30 cases).
the main study endpoints were six-month progression-free survival (PFS-6), while biomarkers were evaluated, including PD-L1 expression, tumor-immersed lymphocyte (TIL) density, immunoactivated gene expression characteristics, and plasma-related cytokines.
to evaluate nerve function using the Neurologic Assessment in Neuro-Oncology scale, NANO.
study, the researchers found that patients with relapsed GBM had good resistance to Pabliju monodratives or combined beval beads, but had limited clinical efficacy.
group A patients had PFS-6 of 26.0% (95% CI, 16.3-41.5), a medium total lifetime (OS) of 8.8 months (95% CI, 7.7-14.2), an overall response rate (ORR) of 20%, and a medium mitigation time of 48 weeks.
group B patients had 6.7% PFS-6 (95% CI, 1.7-25.4), while the medium OS was 10.3 months (95% CI, 8.5-12.5) and ORR was 0%.
tumor immunomarkers are not associated with OS.
group A patients with shorter OS were associated with baseline seromisson use, post-treatment plasma VEGF expression, IDH1 mutation and MGMT methylation status.
group B patients were associated with elevated levels of baseline placental growth factors (PlGF) and sVEGFR1.
Conclusions In summary, Paboli pearl monoantigen, whether single-drug or combined beva-bead monoantigen therapy relapsed GBM is not effective, tumor immunobimarkers can not judge prognostic.
the biomarkers of GBM immunotherapy in the state of cymxymeth and MGMT methylation require further study.
: The intellectual property rights of the content published by the Brain Medical Exchange's Extra-God Information, God-based Information and Brain Medicine Consulting are owned by the Brain Medical Exchange and the organizers, the original authors and other relevant rights persons.
, editing, copying, cutting, recording, etc. without permission.
be used with a license, the source must also be indicated.
welcome to forward and share.